# How Engineered Antibodies Block Inflammation-Causing Proteins

> A patent describing lab-made antibodies designed to hunt down and neutralize a specific protein called TNF-alpha that causes chronic inflammation in the body.

- **Patent:** US 7070775
- **Original title:** Recombinant A2-specific TNFα specific antibodies
- **Owner:** Centocor Inc
- **Granted:** 2006
- **Status:** Public domain (expired)
- **Times cited:** 77
- **Field:** biotech, pharmaceutical

## What it does

This patent covers specific recombinant antibodies engineered to bind to human tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is a protein that acts like an alarm bell for the immune system, but when it stays on too long, it causes diseases like rheumatoid arthritis or Crohn's. The patent claims antibodies that mimic the binding behavior of a specific reference antibody called A2. By attaching to TNF-alpha, these antibodies prevent the protein from triggering the inflammatory response in cells. The claims specify that these antibodies must have a human constant region to be better tolerated by the human immune system and must meet a high threshold of binding strength, measured by a Scatchard analysis.

## What it does NOT cover

- Does not cover antibodies that bind to TNF-alpha but do not compete with the A2 reference antibody.
- Does not cover natural, non-recombinant antibodies found in living organisms.
- Does not cover therapeutic methods that use small molecule drugs instead of antibody-based proteins.
- Does not cover antibodies that fail to meet the specific binding affinity threshold of 1x10^8 liter/mole.

## The clever bit

The innovation lies in creating a chimeric or humanized antibody that retains the high-affinity binding of a mouse-derived antibody (A2) while incorporating human protein sequences to avoid triggering an immune attack against the drug itself.

## Real-world examples

1. Infliximab (Remicade)
2. Monoclonal antibody therapies for autoimmune diseases
3. Biologic drugs targeting TNF-alpha

## Why it matters

This technology is central to the development of biologic drugs, which have transformed the treatment of autoimmune diseases. By using recombinant DNA technology to create humanized antibodies, researchers were able to create treatments that the human body does not immediately reject. This patent relates to the lineage of therapies like Remicade (infliximab), which revolutionized how doctors manage conditions like Crohn's disease and ulcerative colitis.

## Frequently asked questions

### What does How Engineered Antibodies Block Inflammation-Causing Proteins cover?

A patent describing lab-made antibodies designed to hunt down and neutralize a specific protein called TNF-alpha that causes chronic inflammation in the body.

### Who owns patent US 7070775?

Centocor Inc owns this patent, granted in 2006.

### When does this patent expire?

This patent is expected to expire on July 4, 2026, when the invention enters the public domain.

### What is patent US 7070775 cited by?

This patent has been cited by 77 later patents that build on its ideas.

### What problem does this patent solve?

This technology is central to the development of biologic drugs, which have transformed the treatment of autoimmune diseases. By using recombinant DNA technology to create humanized antibodies, researchers were able to create treatments that the human body does not immediately reject. This patent relates to the lineage of therapies like Remicade (infliximab), which revolutionized how doctors manage conditions like Crohn's disease and ulcerative colitis.

### What does this patent NOT cover?

Does not cover antibodies that bind to TNF-alpha but do not compete with the A2 reference antibody.

**Full plain-English explainer:** https://patentbrief.org/patent/us/7070775/humira-formulation

**Original patent:** https://patents.google.com/patent/US7070775

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._